An essential requirement for the licensing of new antibiotics is the provision of data on efficacy and safety obtained from clinical trials in which patients are randomized to receive either the experimental drug or a comparator antibiotic regarded as a standard treatment option. Preface.
Alan Johnson*, Leonard Leibovici
*Corresponding author for this work
Research output: Contribution to journal › Editorial